A game changing LATITUDE: Role of abiraterone plus prednisone in metastatic hormonesensitive prostate cancer. [corrected]
- PMID: 29021663
- PMCID: PMC5635680
- DOI: 10.4103/iju.IJU_250_17
A game changing LATITUDE: Role of abiraterone plus prednisone in metastatic hormonesensitive prostate cancer. [corrected]
Erratum in
-
Erratum: A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormonesensitive prostate cancer.Indian J Urol. 2019 Apr-Jun;35(2):175. doi: 10.4103/2277-9175.241837. Indian J Urol. 2019. PMID: 31000930 Free PMC article.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
Erratum: A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormonesensitive prostate cancer.Indian J Urol. 2019 Apr-Jun;35(2):175. doi: 10.4103/2277-9175.241837. Indian J Urol. 2019. PMID: 31000930 Free PMC article.
-
Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study.Jpn J Clin Oncol. 2020 Jul 9;50(7):810-820. doi: 10.1093/jjco/hyaa030. Jpn J Clin Oncol. 2020. PMID: 32188988 Free PMC article. Clinical Trial.
-
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8. Lancet Oncol. 2018. PMID: 29326030 Clinical Trial.
-
[Abiraterone plus prednisone in patients with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)].Aktuelle Urol. 2019 Dec;50(6):625-628. doi: 10.1055/a-0852-3405. Epub 2019 Mar 27. Aktuelle Urol. 2019. PMID: 30919390 Review. German.
-
Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.Ther Adv Med Oncol. 2017 May;9(5):319-333. doi: 10.1177/1758834017698644. Epub 2017 Mar 22. Ther Adv Med Oncol. 2017. PMID: 28529549 Free PMC article. Review.
Cited by
-
Erratum: A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormonesensitive prostate cancer.Indian J Urol. 2019 Apr-Jun;35(2):175. doi: 10.4103/2277-9175.241837. Indian J Urol. 2019. PMID: 31000930 Free PMC article.
References
-
- Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60. - PubMed
-
- Gandaglia G, Fossati N, Suardi N, Montorsi F, Briganti A. STAMPEDE trial and patients with non-metastatic prostate cancer. Lancet. 2016;388:234–5. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources